Susquehanna Fundamental Investments’s Beam Therapeutics BEAM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$535K	Buy	+15,600	New	+$471K	0.01%	552
2026 Q1	–	Sell	-21,025	Closed	-$583K	–	502
2025 Q4	$583K	Sell	21,025 -1,811	-8%	-$46.2K	0.02%	411
2025 Q3	$554K	Sell	22,836 -14,769	-39%	-$294K	0.02%	424
2025 Q2	$640K	Sell	37,605 -36,253	-49%	-$631K	0.02%	513
2025 Q1	$1.44M	Buy	73,858 +21,133	+40%	+$554K	0.02%	604
2024 Q4	$1.31M	Buy	+52,725	New	+$1.35M	0.02%	638

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Susquehanna Fundamental Investments's BEAM Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 15,600 shares worth $535K. The stake represents 0.01% of the portfolio and ranks #552 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in BEAM as recently as Q4 2025.

Susquehanna Fundamental Investments first reported a position in BEAM in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.44M in Q1 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Susquehanna Fundamental Investments held 15,600 shares of Beam Therapeutics worth $535K as of Q2 2026.
Beam Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
Beam Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #552 holding.
Susquehanna Fundamental Investments first reported a position in Beam Therapeutics in Q4 2024 and has held it in 6 quarters since.
Susquehanna Fundamental Investments's Beam Therapeutics position peaked at $1.44M in Q1 2025.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.